|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanistic discussion is placed in the context of completed and ongoing trials of SGLT2 inhibitors in the prevention and treatment of heart failure in individuals with and without diabetes.
|
30132036 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focusses on the effects of SGLT2 inhibitors on the kidney and renal outcome: it briefly outlines renal glucose handling in diabetes and its role in glomerular hyperfiltration and renal hypoxia; describes how SGLT2 inhibitors induce an early, reversible reduction in glomerular filtration rate (GFR) and preserve GFR in the long-term in patients with T2DM; discusses whether the enhanced active transport in the renal outer medulla (OM) in response to SGLT2 inhibition is friend or foe; proposes how the blood pressure lowering and heart failure protective effect of SGLT2 inhibitors can be preserved in chronic kidney disease (CKD) despite attenuated antihyperglycemic effects; and examines whether SGLT2 inhibition enhances the incidence or severity of acute kidney injury (AKI).
|
29954951 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, improvement of overall CV outcomes was likely driven by reduction in HF-related events in trials investigating SGLT2 inhibitors, and by reduction in atherosclerotic events in those investigating GLP-1RAs.
|
29895290 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.
|
30519189 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current evidence suggests that SGLT-2 inhibitors are more effective than either GLP-1 agonists or DPP-4 inhibitors for reducing the risk of hospitalization for HF in type 2 diabetes mellitus.
|
30196071 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
This prospective multicenter trial showed the beneficial effect of SGLT2 inhibitors on LV diastolic functional parameters for T2DM patients with HF.
|
30296931 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects and Safety of Sodium Glucose Cotransporter 2 Inhibitors in Diabetes Patients With Drug-Refractory Advanced Heart Failure.
|
29695659 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SGLT-2 inhibitors were significantly associated with lower rates of HF events (absolute RD, -1.1%; HR, 0.62 [95% CrI, 0.54 to 0.72]) and MI (absolute RD, -0.6%; HR, 0.86 [95% CrI, 0.77 to 0.97]) than were the control groups.
|
29677303 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
|
30472914 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EMPA-OUTCOME trial involving empagliflozin (a SGLT-2 receptor inhibitor) has shown significant reductions in major adverse cardiac events (MACEs), cardiovascular mortality, and hospitalization for heart failure (HF) when administered on top of standard-of-care therapy for T2DM patients at high CV risk.
|
29679303 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the cardiovascular system, it is likely that plasma volume contraction due to natriuresis in response to SGLT2 inhibition is at least in part responsible for the reduction in the risk of heart failure observed in these trials.
|
30066584 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
We particularly favour SGLT2 inhibitors in those where additional weight loss and blood pressure reductions are desired, and in patients with heart failure or cardiovascular disease.
|
29320602 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Trial sequential analysis provided firm evidence of a 20% reduction in major adverse cardiac events, all-cause mortality, and hospitalization for heart failure with SGLT2 inhibitors, but evidence remains inconclusive for cardiovascular mortality.
|
29353233 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current overview article summarises these aspects and discusses future treatment strategies with SGLT2 inhibitors in diabetic and non-diabetic individuals with chronic kidney disease, liver disease and heart failure.
|
30132035 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the newest antidiabetic medications, sodium-glucose cotransporter 2 (SGLT2) inhibitors, have shown to significantly reduce CV mortality and heart failure (HF) hospitalizations.
|
30463454 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Use of SGLT2 inhibitors in specific groups (e.g. those with nocturnal hypertension, diabetes, and high salt sensitivity) could help reduce the risk of heart failure and cardiovascular mortality.
|
30586745 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will summarize key findings of the impact of glucose-lowering agents on CV safety and HF-associated outcomes, present available data on the underlying mechanisms for the benefits of the SGLT2 inhibitors on HF, and discuss strategies to improve outcomes in patients with DM and high CV risk.
|
29270818 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, there may be some exciting new benefits of SGLT2 inhibitors for patients with heart failure.These research studies are underway.
|
30406850 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials with SGLT2 inhibitors in heart failure are positioned to confirm or refute the hypothesis that these drugs may favourably influence the course of obesity-related HFpEF by their ability to attenuate the secretion and actions of leptin.
|
29359851 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EMPA-REG OUTCOME study revealed that a sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, can remarkably reduce cardiovascular (CV) mortality and heart failure in patients with high-risk type 2 diabetes.
|
30093883 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, perhaps the most important finding has been that sodium/glucose cotransporter 2 (SGLT2; also known as SLC5A2) inhibitors reduce heart failure hospitalizations and, in the case of empagliflozin, markedly reduce the rate of cardiovascular death.
|
29368701 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
|
29024278 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The remarkable reduction in cardiovascular (CV) mortality (38%), major CV events (14%), hospitalization for heart failure (35%), and death from any cause (32%) observed over a period of 2.6 years in patients with T2D and high CV risk in the EMPA-REG OUTCOME trial involving the SGLT2 inhibitor empagliflozin (Empa) have raised the possibility that potential novel, more specific mechanisms of SGLT2 inhibition synergize with the known modest systemic improvements, such as glycemic, body weight, diuresis, and blood pressure control.
|
29322280 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
|
29938883 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
|
29415819 |
2018 |